Background
Theodore DeWeese is dean of the medical faculty and CEO, Johns Hopkins Medicine. Dr. DeWeese is the Sidney Kimmel Professor of Radiation Oncology and Molecular Radiation Sciences, and is professor of oncology and urology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include prostate cancer, radiation oncology and urological oncology.
He and his colleagues focus their research on developing new ways to enhance radiation-induced killing of prostate cancer cells. This includes development of novel, prostate cancer-targeted RNA molecules as well as new ways to modulate androgen receptor signaling. He and his colleagues also developed the first adenoviral gene therapy trial for prostate cancer, using a common cold virus to target cancer cells while leaving normal cells unharmed.
Dr. DeWeese earned his M.D. from the University of Colorado Health Sciences Center. He completed his residency at The Johns Hopkins Hospital, serving as chief resident, and performed a laboratory research fellowship at the Johns Hopkins Oncology Center and the James Buchanan Brady Urological Institute.
Dr. DeWeese's research interests include prostate cancer, DNA damage, and radiation sensitization.
Dr. DeWeese has served on numerous committees and boards including as President and Chair of the Board for the American Society for Radiation Oncology. He also serves on committees for the American Association for Cancer Research and was appointed by the National Academy of Sciences as a scientific counselor for the Radiation Effects Research Foundation in Hiroshima, Japan. He has received numerous awards and honors, including several teaching awards from Johns Hopkins.
Patient Ratings & Comments
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.